Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma

Lo,Paulisally Hau Yi; Tanikawa,Chizu; Katagiri,Toyomasa; Nakamura,Yusuke; Matsuda,Koichi

doi:10.3892/or.2014.3581

Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma

Authors:
- Paulisally Hau Yi Lo
- Chizu Tanikawa
- Toyomasa Katagiri
- Yusuke Nakamura
- Koichi Matsuda
View Affiliations

Affiliations: Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, Division of Genome Medicine, Institute for Genome Research, The University of Tokushima, Tokushima, Japan, Departments of Medicine and Surgery, and Center for Personalized Therapeutics, The University of Chicago, Chicago, IL, USA
Published online on: November 3, 2014 https://doi.org/10.3892/or.2014.3581
Pages: 267-273

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Development of cancer is a complex process involving multiple genetic and epigenetic alterations. In our microarray analysis of 81 breast carcinoma specimens, we identified peptidase domain containing associated with muscle regeneration 1 (PAMR1) as being frequently suppressed in breast cancer tissues. PAMR1 expression was also reduced in all tested breast cancer cell lines, while PAMR1 was expressed moderately in normal breast tissues and primary mammary epithelial cells. DNA sequencing of the PAMR1 promoter after sodium bisulfite treatment revealed that CpG sites were hypermethylated in the breast cancer tissues and cell lines. PAMR1 expression was restored by 5-aza-2' deoxycytidine treatment, demonstrating that promoter hypermethylation contributed to PAMR1 inactivation in the breast cancer cells. In addition, ectopic expression of PAMR1 markedly suppressed cancer cell growth. In summary, our study identified PAMR1 as a putative tumor suppressor which was frequently inactivated by promoter hypermethylation in breast cancer tissues.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Campo E: Whole genome profiling and other high throughput technologies in lymphoid neoplasms - current contributions and future hopes. Mod Pathol. 26:S97–S110. 2013. View Article : Google Scholar
3	Ajiro M, Katagiri T, Ueda K, et al: Involvement of RQCD1 over-expression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 35:673–681. 2009.PubMed/NCBI
4	Kim JW, Fukukawa C, Ueda K, Nishidate T, Katagiri T and Nakamura Y: Involvement of C12orf32 overexpression in breast carcinogenesis. Int J Oncol. 37:861–867. 2010.PubMed/NCBI
5	Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y and Katagiri T: Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci. 98:174–181. 2007. View Article : Google Scholar : PubMed/NCBI
6	Shimo A, Tanikawa C, Nishidate T, et al: Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 99:62–70. 2008.
7	Kim JW, Akiyama M, Park JH, et al: Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 100:1468–1478. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yoshimaru T, Komatsu M, Matsuo T, et al: Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun. 4:24432013. View Article : Google Scholar : PubMed/NCBI
9	Agrawal A, Murphy RF and Agrawal DK: DNA methylation in breast and colorectal cancers. Mod Pathol. 20:711–721. 2007. View Article : Google Scholar : PubMed/NCBI
10	Yu Z, Xiao Q, Zhao L, et al: DNA methyltransferase 1/3a over-expression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis. Mol Carcinog. Jan 25–2014.(Epub ahead of print). View Article : Google Scholar
11	Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W and Zhong XY: Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene. 28:2969–2978. 2009. View Article : Google Scholar : PubMed/NCBI
12	Niwa Y, Oyama T and Nakajima T: BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res. 91:519–526. 2000. View Article : Google Scholar : PubMed/NCBI
13	Barekati Z, Radpour R, Lu Q, et al: Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer. 12:2442012. View Article : Google Scholar : PubMed/NCBI
14	Van De Voorde L, Speeckaert R, Van Gestel D, et al: DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res. 751:304–325. 2012. View Article : Google Scholar : PubMed/NCBI
15	Medina-Franco JL and Caulfield T: Advances in the computational development of DNA methyltransferase inhibitors. Drug Discov Today. 16:418–425. 2011. View Article : Google Scholar : PubMed/NCBI
16	Schrump DS, Fischette MR, Nguyen DM, et al: Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 12:5777–5785. 2006. View Article : Google Scholar : PubMed/NCBI
17	Issa JP, Kantarjian HM and Kirkpatrick P: Azacitidine. Nature Rev Drug Discov. 4:275–276. 2005. View Article : Google Scholar
18	Lin J, Deng Z, Tanikawa C, et al: Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation. Int J Oncol. 44:1490–1498. 2014.PubMed/NCBI
19	Nishidate T, Katagiri T, Lin ML, et al: Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 25:797–819. 2004.PubMed/NCBI
20	Tanikawa C, Furukawa Y, Yoshida N, Arakawa H, Nakamura Y and Matsuda K: XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene. 28:3081–3092. 2009. View Article : Google Scholar : PubMed/NCBI
21	Clark HF, Gurney AL, Abaya E, et al: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 13:2265–2270. 2003. View Article : Google Scholar : PubMed/NCBI
22	Nakayama Y, Nara N, Kawakita Y, et al: Cloning of cDNA encoding a regeneration-associated muscle protease whose expression is attenuated in cell lines derived from Duchenne muscular dystrophy patients. Am J Pathol. 164:1773–1782. 2004. View Article : Google Scholar : PubMed/NCBI
23	Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
24	Gao Y, Niu Y, Wang X, et al: Chromosome aberrations associated with centrosome defects: a study of comparative genomic hybridization in breast cancer. Hum Pathol. 42:1693–1701. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hawthorn L, Luce J, Stein L and Rothschild J: Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast. BMC Cancer. 10:4602010. View Article : Google Scholar : PubMed/NCBI
26	Huang Y, Bove B, Wu Y, et al: Microsatellite instability during the immortalization and transformation of human breast epithelial cells in vitro. Mol Carcinog. 24:118–127. 1999. View Article : Google Scholar : PubMed/NCBI
27	Cheng CJ, Lin YC, Tsai MT, et al: SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res. 69:3634–3641. 2009. View Article : Google Scholar : PubMed/NCBI
28	Lin YC, Lee YC, Li LH, Cheng CJ and Yang RB: Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 127:85–100. 2014. View Article : Google Scholar
29	Lin YC, Chen CC, Cheng CJ and Yang RB: Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. J Biol Chem. 286:27039–27047. 2011. View Article : Google Scholar : PubMed/NCBI